Key result
Spironolactone significantly downregulated HCN2 and HCN4 protein expression by 50% and 52%, respectively, and increased miRNA-1 levels in ischemic rat myocardium after myocardial infarction.
Why the study?
Does spironolactone regulate HCN protein expression through miRNA-1 in a rat model of myocardial infarction?
Does spironolactone regulate HCN protein expression through miRNA-1 in a rat model of myocardial infarction?
Spironolactone reduces HCN2 and HCN4 protein expression in ischemic rat myocardium post-MI partially through the upregulation of miRNA-1, providing a potential mechanism for its antiarrhythmic effects.
Spironolactone may modulate post-MI HCN expression; leaves open clinical relevance for arrhythmia prevention.
Emerging evidence has shown that aldosterone blockers reduced the incidence of ventricular arrhythmias in patients with myocardial infarction (MI). However, the mechanism remains unknown. In this study, we investigated the mechanism by which spironolactone, a classic aldosterone blocker, regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN) protein expression in ischemic rat myocardium after MI. Eighteen rats surviving 24 hours after MI were randomly assigned into 3 groups: MI, spironolactone, and spironolactone + antagomir-1. Six sham-operated rats had a suture loosely tied around the left coronary artery, without ligation. The border zone of the myocardial infarct was collected from each rat at 1 week after MI. HCN2 and HCN4 protein and messenger RNA (mRNA) level were measured in addition to miRNA-1 levels. Spironolactone significantly increased miRNA-1 levels and downregulated HCN2 and HCN4 protein and mRNA levels. miRNA-1 suppression with antagomir-1 increased HCN2 and HCN4 protein levels; however, HCN2 and HCN4 mRNA levels were not affected. These results suggested that spironolactone could increase miRNA-1 expression in ischemic rat myocardium after MI and that the upregulation of miRNA-1 expression partially contributed to the posttranscriptional repression of HCN protein expression, which may contribute to the effect of spironolactone to reduce the incidence of MI-associated ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2015) studied Myocardial Infarction (n=24). Spironolactone vs. Saline (MI control) and Sham was evaluated on HCN2 and HCN4 protein expression in ischemic left ventricular myocardium (p=<0.05). Spironolactone significantly downregulated HCN2 and HCN4 protein expression by 50% and 52%, respectively, and increased miRNA-1 levels in ischemic rat myocardium after myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: